NCT06703398 — "A Study of GC101 TIL in Advanced Melanoma" trial site landscape

Public-registry site landscape for NCT06703398, “A Study of GC101 TIL in Advanced Melanoma”, a Melanoma study sponsored by Shanghai Juncell Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT06703398 (registry record)
Study title	A Study of GC101 TIL in Advanced Melanoma
Official title	A Multicenter, Randomized, Controlled,Open Label, Phase II Trial of Autologous Tumor Infiltrating Lymphocytes (GC101 TIL) in Subjects With Advanced Melanoma
Sponsor	Shanghai Juncell Therapeutics
Condition(s)	Melanoma
Phase	PHASE2
Listed sites	1
Site countries	China

Recruiting-density context

At Beijing Cancer Hospital — one of the facilities listed on this trial — 26 other studies are actively recruiting Melanoma patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.

Patient-friendly overview of this study: eichor.com/study/NCT06703398.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT06703398 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →